InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking
technologies for the treatment of spinal cord injuries (SCI) and neurotrauma,
today appointed Brian Hess as Interim Chief Science Officer. Mr. Hess, a
former Stryker biomaterials product development specialist, joined InVivo as
its Director of Product Development in February 2012. As Director of Product
Development, Mr. Hess is responsible for managing, developing and maintaining
the pipeline for the entire portfolio of InVivo products. Mr. Hess replaces
Edward Wirth, MD, PhD, who has resigned from his position as Chief Science
Officer for personal reasons.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsManagement
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in